Business Wire

CGTN

11.6.2020 17:14:08 CEST | Business Wire | Press release

Share
CGTN: Super Virus – COVID-19: How We Got Here

The novel coronavirus has so far claimed over 400,000 lives worldwide, according to John Hopkins University. No one knows how dangerous the virus really is and how long the pandemic will last.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005636/en/

To present readers with a clear picture of how we got here, CGTN portrayed seven* hard-hit countries in an interactive Super Virus . These countries – China, South Korea, the U.S., Germany, France, Italy and the UK – all reported initial confirmed cases at an early stage of the outbreak and all have their relatively mature healthcare systems strained in the fight against it. But their different policy measures have resulted in varied outcomes.

While it’s far too early to draw simple conclusions, the policy measures taken in each country do require scrutiny. The interactive takes a comparative approach in visualizing when and how quickly these measures were enacted over the course of the pandemic. CGTN compiled and analyzed data in the realms of testing, which is crucial to early detection, preventive measures including economic shutdowns and cancellation of public gatherings, as well as the development of clinical methods and the ultimate panacea – an effective vaccine.

Actions taken by countries in regards to testing in the early days appear to have contributed to huge differences down the road. Italy started out with mass testing but then scaled back to only focus on patients who were symptomatic. As the outbreak worsened in Britain, it focused testing and medical resources on critically ill patients.

South Korea and the U.S. reported their first coronavirus cases at almost the same time. But their governments’ attitudes toward testing amid the outbreak couldn’t be more different.

A week after South Korea reported its first case, its health department gathered more than 20 pharmaceutical companies to secure a testing method for COVID-19 that was settled upon eight days later. But weeks after the coronavirus landed in the U.S., there continued to be frustration over shortcomings in diagnostic test distribution and flawed test kits. First there was an outcry over the red tape in getting COVID-19 testing kits approved, then came confusion over who could get a test.

As for travel restrictions, border controls of different types were adopted by many of the six countries. Measures ranged from health checks at the airport to travel warnings and restrictions to quarantining returning overseas travelers. A latecomer to border controls, China didn’t implement restrictions until the end of March when global cases had already exploded.

Such a policy came with extreme measures in certain countries. The Trump administration suspended immigration to the U.S. for 60 days in the name of protecting domestic workers as unemployment hit a record high amid the coronavirus. But this policy left numerous families and businesses reeling instead of boosting employment.

Early-stage border controls also contributed to one problem: Most Western countries neglected prevention and control within their borders.

Restrictions on the movement of peoples within national borders were implemented with varying degrees of effectiveness. Most of the six countries, for instance, adopted stay-at-home orders ahead of lockdowns, except China. In the early morning of January 23, over 20 days after the first known cluster of cases was reported, Wuhan launched a severe lockdown, barring all cars, trains, planes in and out, which lasted 76 days.

In Italy, where similar measures were taken in the country’s northern Lombardy and Veneto – that, combined, makes up 30 percent of the Italian economy, residents were subjected to mandatory home quarantines with all non-essential businesses closed. Meanwhile, some of the other countries like the U.S. and the UK skipped imposing mandatory quarantines in the early stages due to various reasons.

COVID-19 caught the whole world off guard, exposing how we are underprepared in the face of a pandemic of such a scale and scope. The virus has grievously overburdened even the world’s best healthcare systems, with all the seven countries suffering from a dearth of medical professionals and supplies. Doctors and nurses continue to face the danger of being infected, and the psychological burden that they may spread the disease to other patients, or lost their jobs when back from the frontline.

The coronavirus is also not an equal offender — it has disproportionately affected historically marginalized populations. Rates of infection and death from the coronavirus are higher for African and Native Americans, who are on average poorer than their white counterparts. When it comes to age, the elderly makes up a sizable portion of all deaths, due to complications from the coronavirus on top of other conditions. Indigenous peoples are also experiencing higher rates of infection than the national averages of the countries they reside in. In Europe, the Roma live in overcrowded shantytowns, making them particularly affected by the outbreak given the lack of sanitary living conditions.

While outbreaks continue in many of these countries with advanced medical development, the future doesn’t seem to be defined by doom and gloom . Since the outbreak began in January, hundreds of universities, pharmaceutical companies and international organizations have participated in some 320 trials looking into various treatments for COVID-19. Given how divisive COVID-19 has been, the immense scale of this endeavor calls for cooperation across nations, organizations and societies. While time is the best asset for a rapidly spreading pandemic, it is not too late to cultivate this spirit of cooperation.

* The mobile version of the interactive only focuses on six countries for optimal user experience.

Original article: https://news.cgtn.com/news/2020-06-09/Super-Virus-COVID-19-How-we-got-here--Ra9s4L7rBC/index.html

Link:

ClickThru

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye